Literature DB >> 12370276

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells.

Robin Parihar1, Julie Dierksheide, Yan Hu, William E Carson.   

Abstract

The anti-tumor activity of recombinant mAb's directed against tumor cell growth receptors has generally been considered to result from direct antiproliferative effects, the induction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets. However, it remains unclear to what degree these mechanisms actually aid in the clearance of Ab-coated tumor cells in vivo. We show here that NK cells secrete a distinct profile of potent immunostimulatory cytokines in response to dual stimulation with Ab-coated tumor cells and IL-12. This response could not be duplicated by costimulation with other ILs and was significantly enhanced in the presence of monocytes. Cytokine production was dependent upon synergistic signals mediated by the activating receptor for the Fc portion of IgG (FcgammaRIII) and the IL-12 receptor expressed on NK cells. Coadministration of Ab-coated tumor cells and IL-12 to BALB/c mice resulted in enhanced circulating levels of NK cell-derived cytokines with the capacity to augment anti-tumor immunity. These findings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor activity of mAb's might also result from activation of a potent cytokine secretion program within immune effectors capable of recognizing mAb-coated targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370276      PMCID: PMC151155          DOI: 10.1172/JCI15950

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  57 in total

1.  Clinical evaluation of the bispecific antibody MDX-H210 (anti-Fc gamma RI x anti-HER-2/neu) in combination with granulocyte-colony-stimulating factor (filgrastim) for treatment of advanced breast cancer.

Authors:  H H van Ojik; R Repp; G Groenewegen; T Valerius; J G van de Winkel
Journal:  Cancer Immunol Immunother       Date:  1997 Nov-Dec       Impact factor: 6.968

Review 2.  The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses.

Authors:  M K Gately; L M Renzetti; J Magram; A S Stern; L Adorini; U Gubler; D H Presky
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

3.  Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12.

Authors:  J H Chace; N A Hooker; K L Mildenstein; A M Krieg; J S Cowdery
Journal:  Clin Immunol Immunopathol       Date:  1997-08

4.  Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.

Authors:  B Gerstmayer; M Hoffmann; U Altenschmidt; W Wels
Journal:  Cancer Immunol Immunother       Date:  1997 Nov-Dec       Impact factor: 6.968

5.  Stress and immune responses after surgical treatment for regional breast cancer.

Authors:  B L Andersen; W B Farrar; D Golden-Kreutz; L A Kutz; R MacCallum; M E Courtney; R Glaser
Journal:  J Natl Cancer Inst       Date:  1998-01-07       Impact factor: 13.506

6.  Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-gamma in murine tumors.

Authors:  S J Yoon; D S Heo; J O Kang; S G Lee; C D Kim; M W Sung; N K Kim
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

7.  Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

Authors:  M D Pegram; A Lipton; D F Hayes; B L Weber; J M Baselga; D Tripathy; D Baly; S A Baughman; T Twaddell; J A Glaspy; D J Slamon
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

8.  Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII.

Authors:  L M Weiner; J I Clark; M Davey; W S Li; I Garcia de Palazzo; D B Ring; R K Alpaugh
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

9.  Interleukin-12 increases bispecific-antibody-mediated natural killer cell cytotoxicity against human tumors.

Authors:  U Sahin; S Kraft-Bauer; S Ohnesorge; M Pfreundschuh; C Renner
Journal:  Cancer Immunol Immunother       Date:  1996-01       Impact factor: 6.968

Review 10.  Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.

Authors:  S D Scott
Journal:  Cancer Pract       Date:  1998 May-Jun
View more
  90 in total

1.  miR-155 regulates IFN-γ production in natural killer cells.

Authors:  Rossana Trotta; Li Chen; David Ciarlariello; Srirama Josyula; Charlene Mao; Stefan Costinean; Lianbo Yu; Jonathan P Butchar; Susheela Tridandapani; Carlo M Croce; Michael A Caligiuri
Journal:  Blood       Date:  2012-02-29       Impact factor: 22.113

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

3.  Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.

Authors:  Eric Luedke; Alena Cristina Jaime-Ramirez; Neela Bhave; Julie Roda; Moaz Maqbool Choudhary; Bhavna Kumar; Theodoros N Teknos; William E Carson
Journal:  Surgery       Date:  2012-07-06       Impact factor: 3.982

4.  IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells.

Authors:  Elizabeth L McMichael; Alena Cristina Jaime-Ramirez; Kristan D Guenterberg; Eric Luedke; Lakhvir S Atwal; Amanda R Campbell; Zhiwei Hu; Armika S Tatum; Sri Vidya Kondadasula; Xiaokui Mo; Susheela Tridandapani; Mark Bloomston; E Christopher Ellison; Terence M Williams; Tanios Bekaii-Saab; William E Carson
Journal:  Clin Cancer Res       Date:  2016-07-19       Impact factor: 12.531

5.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

Review 6.  Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy.

Authors:  Carsten Denkert; Silvia Darb-Esfahani; Sibylle Loibl; Ioannis Anagnostopoulos; Korinna Jöhrens
Journal:  Semin Immunopathol       Date:  2011-04-17       Impact factor: 9.623

7.  A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

Authors:  Aruna Mani; Julie Roda; Donn Young; Michael A Caligiuri; Gini F Fleming; Peter Kaufman; Adam Brufsky; Susan Ottman; William E Carson; Charles L Shapiro
Journal:  Breast Cancer Res Treat       Date:  2008-12-03       Impact factor: 4.872

8.  FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Authors:  Nada S Alakhras; Jiabin Qiu; Guilherme V Rocha; Derrick R Witcher; Anja Koester; Jinsam You; David A Schaer; Rikke B Holmgaard; Kyla Driscoll; Jeffrey A Willy; Laurent P Malherbe
Journal:  MAbs       Date:  2018-07-26       Impact factor: 5.857

9.  MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions.

Authors:  Amanda R Campbell; Megan C Duggan; Lorena P Suarez-Kelly; Neela Bhave; Kallan S Opheim; Elizabeth L McMichael; Prashant Trikha; Robin Parihar; Eric Luedke; Adrian Lewis; Bryant Yung; Robert Lee; David Raulet; Susheela Tridandapani; Veronika Groh; Lianbo Yu; Vedat Yildiz; John C Byrd; Michael A Caligiuri; William E Carson
Journal:  Cancer Immunol Res       Date:  2017-07-19       Impact factor: 11.151

10.  Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells.

Authors:  Keunok Jung; Ji-Hee Ha; Jung-Eun Kim; Jeong-Ah Kim; Ye-Jin Kim; Chul-Ho Kim; Yong-Sung Kim
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.